Esperion (NASDAQ: ESPR) today announced the nomination of ESP-2001, the Company’s highly-specific allosteric ATP citrate lyase (ACLY) inhibitor, as preclinical development candidate for the treatment ...

Given the unmet need of fatigue in primary biliary cholangitis (PBC), the PBC working group of the European Reference Network for Rare Liver Diseases assessed and summarised the current evidence ...

DelveInsight’s, “Primary Biliary Cholangitis Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Primary Biliary Cholangitis pipeline landscape.

PARIS — Statins can significantly reduce the risk for complications and death from primary sclerosing cholangitis, results from a Swedish registry study show. Primary sclerosing cholangitis is ...

In March, Shelby Dixon was diagnosed with stage 4 high-grade neuroendocrine carcinoma, 12 years after she underwent a liver ...

The cholangitis infection is often caused by bacteria, a gallstone or any another blockage. Primary biliary cholangitis is a chronic condition where inflammation of the bile duct system keeps bile ...

This open-label, international, long-term extension study, evaluated the efficacy and safety of seladelpar a potent, selective, orally active PPARδ agonist, or delpar, through 2 years of treatment in ...

Morgan Stanley raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $81 from $75 and keeps an Overweight rating on the shares. For volixibat, which the firm believes “could drive the next ...

Mirum Pharmaceuticals’ MIRM lead product, Livmarli (maralixibat), has been driving the majority of the company’s revenues.

In patients with primary biliary cholangitis, biochemical non-response to obeticholic acid as a second-line therapy may ...

TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory ...